Eli Lilly & Co. raised its full-year guidance as revenue from its blockbuster weight loss and diabetes drugs beat ...
Zacks Investment Research on MSN
Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales
Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks ...
Johnson & Johnson's Tremfya is the first IL-23 inhibitor to gain FDA approval in a paediatric population for plaque psoriasis.
Key Points Chesapeake sold 9,875 Eli Lilly and Company shares; estimated trade value of approximately $7.68 million, based on the average price for Q2 2025 Transaction represented 6.9% of fund AUM.
According to a filing with the Securities and Exchange Commission dated October 21, 2025, Generali Asset Management reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback